These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 11345356)

  • 1. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
    Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
    J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?
    Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
    Heart Fail Rev; 2001 Dec; 6(4):301-15. PubMed ID: 11447305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
    Zhang Y; Oliver JR; Horowitz JD
    Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin antagonists and heart failure.
    Hürlimann D; Enseleit F; Noll G; Lüscher TF; Ruschitzka F
    Curr Hypertens Rep; 2002 Feb; 4(1):85-92. PubMed ID: 11790297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function.
    Yamauchi-Kohno R; Miyauchi T; Hoshino T; Kobayashi T; Aihara H; Sakai S; Yabana H; Goto K; Sugishita Y; Murata S
    Circulation; 1999 Apr; 99(16):2171-6. PubMed ID: 10217659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
    Holm P
    Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure.
    Wada A; Tsutamoto T; Fukai D; Ohnishi M; Maeda K; Hisanaga T; Maeda Y; Matsuda Y; Kinoshita M
    J Am Coll Cardiol; 1997 Nov; 30(5):1385-92. PubMed ID: 9350944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men.
    Spratt JC; Goddard J; Patel N; Strachan FE; Rankin AJ; Webb DJ
    Br J Pharmacol; 2001 Oct; 134(3):648-54. PubMed ID: 11588120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism.
    Wada A; Tsutamoto T; Ohnishi M; Sawaki M; Fukai D; Maeda Y; Kinoshita M
    Circulation; 1999 Feb; 99(4):570-7. PubMed ID: 9927406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will endothelin receptor antagonists have a role in heart failure?
    Spieker LE; Lüscher TF
    Med Clin North Am; 2003 Mar; 87(2):459-74. PubMed ID: 12693734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure.
    Ohnishi M; Wada A; Tsutamoto T; Fukai D; Kinoshita M
    Cardiovasc Res; 1998 Sep; 39(3):617-24. PubMed ID: 9861304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
    Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
    Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade.
    Burkhardt M; Barton M; Shaw SG
    J Hypertens; 2000 Mar; 18(3):273-9. PubMed ID: 10726713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure.
    Thorin E; Lucas M; Cernacek P; Dupuis J
    Am J Physiol Heart Circ Physiol; 2000 Aug; 279(2):H844-51. PubMed ID: 10924085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators.
    Spieker LE; Mitrovic V; Noll G; Pacher R; Schulze MR; Muntwyler J; Schalcher C; Kiowski W; Lüscher TF
    J Am Coll Cardiol; 2000 Jun; 35(7):1745-52. PubMed ID: 10841220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure.
    Ohnishi M; Wada A; Tsutamoto T; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Wang X; Kinoshita M
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():241S-244S. PubMed ID: 12193095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors.
    Love MP; Haynes WG; Gray GA; Webb DJ; McMurray JJ
    Circulation; 1996 Nov; 94(9):2131-7. PubMed ID: 8901663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.
    Mulder P; Richard V; Bouchart F; Derumeaux G; Münter K; Thuillez C
    Cardiovasc Res; 1998 Sep; 39(3):600-8. PubMed ID: 9861302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease.
    Schulze-Neick I; Li J; Reader JA; Shekerdemian L; Redington AN; Penny DJ
    J Thorac Cardiovasc Surg; 2002 Sep; 124(3):435-41. PubMed ID: 12202858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.